title: Neuritic leprosy: further progression and significance.
abstract: Sixteen neuritic cases have been seen developing cutaneous lesions. These cutaneous lesions by and large appear within 4 months after the diagnosis of neuritic leprosy. Leprosy pathology in cutaneous lesions has been found ranging between indeterminate and borderline lepromatous group. Development of cutaneous lesions does not seem to be influenced by age, sex or number of nerves or lepromin status. Neither lesions seem to appear in any particular part of the body. Therapy, duration and type i.e. monodrug or multidrug, also does not seem to influence the development of cutaneous lesions in either way. It appears that neuritic cases with either very early (indeterminate) or with advanced multibacillary neural pathology may develop skin lesions. Skin lesion possibly appear following reversal reaction in skin. Cases with newly developed skin lesions well respond to standard therapy. Development of cutaneous lesions by neuritic cases possibly indicates towards the natural history of the disease, conforming to the hypothesis that leprosy is basically neural in inception and that all other forms emerge from it.
authors.affiliation: Central JALMA Institute for Leprosy Research (ICMR), Tajganj Agra, Inde.
authors.forename: B
authors.initials: B
authors.lastname: Mishra
authors.forename: A
authors.initials: A
authors.lastname: Mukherjee
authors.forename: A
authors.initials: A
authors.lastname: Girdhar
authors.forename: S
authors.initials: S
authors.lastname: Husain
authors.forename: G N
authors.initials: GN
authors.lastname: Malaviya
authors.forename: B K
authors.initials: BK
authors.lastname: Girdhar
mesh_terms: D000328:Adult; D001706:Biopsy; D005260:Female; D006801:Humans; D006987:Hypesthesia / Q000209:etiology; D007916:Lepromin; D007917:Leprostatic Agents / Q000627:therapeutic use; D007918:Leprosy / Q000150:complications / Q000473:pathology* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010525:Peripheral Nerves / Q000473:pathology; D010523:Peripheral Nervous System Diseases / Q000209:etiology* / Q000628:therapy; D012867:Skin / Q000294:innervation / Q000382:microbiology / Q000473:pathology*
chemical_list: D007917:Leprostatic Agents; D007916:Lepromin